These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38222740)

  • 1. Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
    Wang Z; Wang Y; Wang S; Ran Q; Peng S; Zhang Y; Zhang J; Zhang D; Wang L; Lan W; Liu Q; Jiang J
    Ann Med Surg (Lond); 2024 Jan; 86(1):245-251. PubMed ID: 38222740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
    Li K; Zhong W; Fan J; Wang S; Yu D; Xu T; Lyu J; Wu S; Qin T; Wu Z; Xu L; Wu K; Liu Z; Hu Z; Li F; Wang J; Wang Q; Min J; Zhang Z; Yu L; Ding S; Huang L; Zhao T; Huang J; Lin T
    Nat Cancer; 2024 Oct; 5(10):1465-1478. PubMed ID: 39256488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
    Sung HH; Kim H; Kim R; Kim CK; Kwon GY; Park W; Song W; Jeong BC; Park SH
    Investig Clin Urol; 2022 Mar; 63(2):168-174. PubMed ID: 35244990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Kim H; Jeong BC; Hong J; Kwon GY; Kim CK; Park W; Pyo H; Song W; Sung HH; Hong JY; Park SH
    Cancer Res Treat; 2023 Apr; 55(2):636-642. PubMed ID: 36228654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases.
    Mao J; Yang C; Xin S; Cui K; Liu Z; Wang T; Hu Z; Wang S; Liu J; Song X; Song W
    Front Med (Lausanne); 2022; 9():949567. PubMed ID: 35979208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
    Hu J; Chen J; Ou Z; Chen H; Liu Z; Chen M; Zhang R; Yu A; Cao R; Zhang E; Guo X; Peng B; Deng D; Cheng C; Liu J; Li H; Zou Y; Deng R; Qin G; Li W; Wang L; Chen T; Pei X; Gong G; Tang J; Othmane B; Cai Z; Zhang C; Liu Z; Zu X
    Cell Rep Med; 2022 Nov; 3(11):100785. PubMed ID: 36265483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial.
    Anari F; O'Neill J; Choi W; Chen DYT; Haseebuddin M; Kutikov A; Dulaimi E; Alpaugh RK; Devarajan K; Greenberg RE; Bilusic M; Wong YN; Viterbo R; Hoffman-Censits JH; Lallas CD; Trabulsi EJ; Smaldone M; Geynisman DM; Zibelman M; Lin J; Kelly WK; Uzzo R; McConkey D; Plimack ER
    Eur Urol Oncol; 2018 May; 1(1):54-60. PubMed ID: 30420974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EFFICACY OF NEOADJUVANT GEMCITABINE AND CISPLATIN IN THE MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER].
    Hashimoto K; Shindo T; Itoh N
    Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):1-6. PubMed ID: 26399123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
    Han S; Ji Z; Jiang J; Fan X; Ma Q; Hu L; Zhang W; Ping H; Wang J; Xu W; Shi B; Wang W; Wang H; Wang H; Chen S; Hu H; Guo J; Zhang S; Jiang S; Zhou Q; Xing N
    Cancer Med; 2023 Jun; 12(11):12106-12117. PubMed ID: 37021811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer.
    Lee FC; Harris W; Cheng HH; Shenoi J; Zhao S; Wang J; Champion T; Izard J; Gore JL; Porter M; Yu EY; Wright JL
    Adv Urol; 2013; 2013():317190. PubMed ID: 24382958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
    Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
    Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade.
    Goel S; Sinha RJ; Bhaskar V; Aeron R; Sharma A; Singh V
    Asian J Urol; 2019 Jul; 6(3):222-229. PubMed ID: 31297313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
    Yang R; Chen JX; Luo SH; Chen TT; Chen LW; Huang B
    World J Clin Cases; 2023 Feb; 11(5):1165-1174. PubMed ID: 36874416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
    North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
    J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.